.gif)
Arcadia Biosciences Announces Second-Quarter and First-Half 2017 Financial Results and Business Highlights
Revenues for the quarter were up 37 percent to $991,000, compared to $721,000 for the second quarter of 2016. The increase reflects higher product sales as well as higher contract and grant revenue, primarily the result of a new agreement. Operating expenses for the second quarter were $4.7 million compared to $5.0 million for the same period in the prior year.
The company’s net loss and net loss attributable to common stockholders in the second quarter of 2017 was $4.0 million, compared to $4.6 million in the comparable period in 2016.
For the first half of 2017, net loss attributable to common stockholders was $8.2 million, an improvement of 16 percent over the comparable period loss of $9.7 million in 2016. Cash on hand and liquid investments at the end of the second quarter totaled $44.1 million.
“Our positive momentum from the first quarter continued in the second quarter with increased revenue, decreased operating costs and a reduced net loss,” said Raj Ketkar, president and CEO of Arcadia. “Together with our global partners, we continue to advance the key products from our yield trait and food ingredient platforms toward commercialization.”
Business and Technology Highlights
Arcadia made the following business and technical achievements during the second quarter of 2017:
- SONOVA GLA Safflower Oil Approved For Use in Dog Food. After completing its review of Arcadia’s food additive petition, the FDA concluded that the data supports the safety and functionality of GLA safflower oil as a source of omega-6 fatty acids in dry food for adult dogs. The petition will be approved when the final rule is published in the Federal Register. This approval opens up an expanded opportunity for use of SONOVA GLA safflower oil in pet nutrition and demonstrates Arcadia’s strong regulatory capabilities and commitment toward creating the greatest possible value for our entire product portfolio.
- Eric J. Rey and Gregory D. Waller Join Arcadia Biosciences Board Of Directors. Eric J. Rey and Gregory D. Waller were elected at the company’s annual stockholders meeting to replace directors Vic Knauf, Ph.D., and Rajiv Shah, M.D. Additionally, the board of directors formally elected George F.J. Gosbee as its chair. Gosbee had served as interim chair of the board since November 2016.
Since the close of the second quarter, Arcadia has also announced the following achievements:
- Arcadia and Dow AgroSciences (DAS) to Collaborate on Improved Wheat Quality Trait. Arcadia and DAS will jointly develop and commercialize a breakthrough improved wheat quality trait in North America. The collaboration leverages Arcadia's leading non-GM TILLING trait development platform with DAS’ enabling technology platforms, high-quality elite germplasm and global commercial channels.
- HB4 Stress-Tolerant Soybeans Complete U.S. FDA Safety Review. Through Verdeca, a joint venture with Bioceres, Arcadia completed the FDA safety review for HB4 stress-tolerant soybeans. This allows products derived from the trait to be used commercially in human food and animal feed. This is a major milestone in the development of this trait, which aims to create significant value for soybean growers by bringing yield stability to areas that experience chronic water stress problems.
- Arcadia’s Water Use Efficiency Trait Completes US Food and Drug Administration Early Food Safety Evaluation (EFSE). The FDA’s EFSE concluded that the functional protein for the WUE trait, isopentenyl transferase (IPT), is safe for humans and animals and would not raise food safety concerns if present in the food supply. This approval is an assurance of safety for WUE crops currently under development and being tested in the field and will expedite the regulatory approvals for this trait. Greenhouse and field trials of the WUE trait have been completed in agronomic crops such as rice, wheat, cotton, peanuts and alfalfa, and Arcadia is currently working with collaborators in rice, potato, sugarcane, cotton and multiple tree species.
- Amy Yoder Joins Arcadia Biosciences Board of Directors. Yoder is president and CEO of Anuvia Plant Nutrients and the former president and CEO of Arysta LifeScience. She received a bachelor’s degree in agricultural technology and systems management from Michigan State University, with an emphasis in crop and soil science.
Arcadia Biosciences, Inc. Financial Snapshot (Unaudited) ($ in thousands)
Three months ended June 30 Six months ended June 30 Favorable/ Favorable/ 2017 2016 (Unfavorable) 2017 2016 (Unfavorable) $ % $ % Total Revenues 991 721 270 37% 2,009 1,573 436 28% Total Operating Expenses 4,728 5,010 282 6% 9,709 10,795 1,086 10% Loss From Operations (3,737) (4,289) 552 13% (7,700) (9,222) 1,522 17% Net Loss and Net Loss Attributable to Common Stockholders (4,006) (4,551) 545 12% (8,222) (9,741) 1,519 16% Revenues
In the second quarter of 2017, revenues were $991,000 compared to revenues of $721,000 in the second quarter of 2016, a 37 percent improvement. The quarter-over-quarter increase was driven by increased product sales and additional revenue from a new contract research agreement in 2017. In the first half of 2017, overall revenues increased to $2.0 million from $1.6 million primarily as a result of the new contract research agreement.
Operating Expenses
In the second quarter of 2017, operating expenses totaled $4.7 million, down from $5.0 million in the first quarter of 2016, a decrease of $282,000 or 6 percent. For the first half of 2017, operating expenses were $9.7 million, compared with $10.8 million during the same period in 2016. Cost of product revenues increased by $40,000 as a result of higher sales when comparing the respective six-month periods. Research and development (R&D) spending decreased by $926,000 and general and administrative (SG&A) expenses decreased by $200,000. Both expense categories had decreases driven primarily by lower salaries and benefits, mainly the result of workforce reductions made during 2016.
Net Loss and Net Loss Attributable to Common Stockholders
Net loss and net loss attributable to common stockholders for the second quarter of 2017 was $4.0 million, or a loss of $0.09 per share, a 12 percent improvement from the $4.6 million loss in the second quarter of 2016. Net loss and net loss attributable to common stockholders for the first half of 2017 was $8.2 million, compared to $9.7 million for the first half of 2016.
Liquidity
Following the close of the second quarter, in July 2017, the Company repaid its outstanding term loan with Silicon Valley Bank, including the principal balance of $25.0 million, interest of $148,000, an early prepayment fee of $500,000 and an end-of-term payment fee of $625,000. Due to the early termination of the facility, management estimates the company will save a total of $2.0 million in cash interest payments over the remaining term of the original facility.
Conference Call and Webcast
The company has scheduled a conference call for 4:30 p.m. Eastern (1:30 p.m. Pacific) today, August 10, to discuss second-quarter financial results and key strategic achievements.
Interested participants can join the conference call using the following numbers:
U.S. Toll-Free Dial-In: +1-844-243-4690 International Dial-In: +1-225-283-0138 Passcode: 58692729 A live webcast of the conference call will be available on the “Investors” section of the Arcadia website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company’s investor website.
Safe Harbor Statement
“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success; the company’s traits, commercial products, and collaborations; and the company’s ability to manage the regulatory processes for its traits and commercial products. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s and its partners’ ability to develop commercial products incorporating its traits and to complete the regulatory review process for such products; the company’s compliance with laws and regulations that impact the company’s business, and changes to such laws and regulations; and the company’s future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company’s financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled “Risk Factors” in the company's Annual Report on Form 10-K for the year ended December 31, 2016. These documents are on the SEC Filings section of the “Investors” section of the company’s website at www.arcadiabio.com. All information provided in this release and in the attachments is as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update this information.
About Arcadia Biosciences, Inc.
Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. For more information, visit www.arcadiabio.com.
Arcadia Biosciences, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except share data)
June 30, December 31, 2017 2016 Assets Current assets: Cash and cash equivalents $ 13,438 $ 2,013 Short-term investments 30,740 48,547 Accounts receivable 432 349 Unbilled revenue 141 184 Inventories — current 286 252 Prepaid expenses and other current assets 1,480 877 Total current assets 46,517 52,222 Property and equipment, net 417 508 Inventories — noncurrent 1,153 1,327 Long-term investments — 2,498 Other noncurrent assets 346 19 Total assets $ 48,433 $ 56,574 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued expenses $ 1,834 $ 2,359 Amounts due to related parties 27 30 Notes payable — current 4,167 — Unearned revenue — current 666 740 Total current liabilities 6,694 3,129 Notes payable — noncurrent 21,058 25,127 Unearned revenue — noncurrent 2,920 3,120 Other noncurrent liabilities 3,000 3,000 Total liabilities 33,672 34,376 Stockholders’ equity: Common stock, $0.001 par value—150,000,000 and 400,000,000
shares authorized as of June 30, 2017 and December 31, 2016;
42,664,821 and 44,487,678 shares issued and outstanding as of
June 30, 2017 and December 31, 201643 44 Additional paid-in capital 174,503 173,723 Accumulated deficit (159,772 ) (151,550 ) Accumulated other comprehensive loss (13 ) (19 ) Total stockholders’ equity 14,761 22,198 Total liabilities and stockholders’ equity $ 48,433 $ 56,574 Arcadia Biosciences, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share data)
Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Revenues: Product $ 195 $ 65 $ 400 $ 320 License 103 140 209 292 Contract research and government grants 693 516 1,400 961 Total revenues 991 721 2,009 1,573 Operating expenses: Cost of product revenues 116 35 222 182 Research and development 1,669 2,216 3,492 4,418 Selling, general and administrative 2,943 2,759 5,995 6,195 Total operating expenses 4,728 5,010 9,709 10,795 Loss from operations (3,737 ) (4,289 ) (7,700 ) (9,222 ) Interest expense (365 ) (327 ) (704 ) (654 ) Other income, net 104 76 200 152 Net loss before income taxes (3,998 ) (4,540 ) (8,204 ) (9,724 ) Income tax provision (8 ) (11 ) (18 ) (17 ) Net loss and net loss attributable to common
stockholders$ (4,006 ) $ (4,551 ) $ (8,222 ) $ (9,741 ) Net loss per share attributable to common stockholders: Basic and diluted $ (0.09 ) $ (0.10 ) $ (0.19 ) $ (0.22 ) Weighted-average number of shares used in per
share calculations:Basic and diluted 42,664,821 44,308,245 43,572,936 44,274,508 Other comprehensive income, net of tax Unrealized gains on available-for-sale securities
7 25 6 109 Other comprehensive income 7 25 6 109 Comprehensive loss attributable to common
stockholders$ (3,999 ) $ (4,526 ) $ (8,216 ) $ (9,632 ) Arcadia Biosciences, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (In thousands)
Six Months Ended June 30, 2017 2016 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ (8,222 ) $ (9,741 ) Adjustments to reconcile net loss to cash used in operating activities: Depreciation and amortization 146 147 Gain on disposal of equipment (3 ) — Net amortization of investment premium and discount (65 ) 139 Stock-based compensation 760 393 Accretion of debt discount 99 98 Changes in operating assets and liabilities: Accounts receivable (83 ) 529 Unbilled revenue 43 (10 ) Inventories 140 (19 ) Prepaid expenses and other current assets (603 ) (670 ) Other noncurrent assets (327 ) (67 ) Accounts payable and accrued expenses (525 ) 195 Amounts due to related parties (3 ) (4 ) Unearned revenue (274 ) 163 Net cash used in operating activities (8,917 ) (8,847 ) CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from sale of property and equipment 4 — Purchases of property and equipment (58 ) (198 ) Purchases of investments (19,405 ) — Proceeds from sales and maturities of investments 39,785 12,205 Net cash provided by investing activities 20,326 12,007 CASH FLOWS FROM FINANCING ACTIVITIES: Payments of debt issuance costs — (46 ) Proceeds from exercise of stock options and ESPP purchases 16 273 Net cash provided by financing activities 16 227 Net increase in cash and cash equivalents 11,425 3,387 Cash and cash equivalents — beginning of period 2,013 23,973 Cash and cash equivalents — end of period $
13,438
$ 27,360 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid for interest $ 599 $ 474 Cash paid for income taxes $ 1 $ 2 NONCASH INVESTING AND FINANCING ACTIVITIES: Exchange of membership interest in unconsolidated entity for common stock $ 2 $ — Stock option exercise cost included in accounts receivable $ — $ 30
ContactsArcadia Biosciences, Inc.
&source=" target="_blank" />
Jeff Bergau
[email protected]
+1-312-217-0419
— Revenues Up, Expenses and Net Loss Down —
DAVIS, Calif.–(BUSINESS WIRE)–Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology
company that creates value for farmers while benefitting the environment
and enhancing human health, today released its financial and business
results for the second quarter and first half of 2017.
Revenues for the quarter were up 37 percent to $991,000, compared to
$721,000 for the second quarter of 2016. The increase reflects higher
product sales as well as higher contract and grant revenue, primarily
the result of a new agreement. Operating expenses for the second quarter
were $4.7 million compared to $5.0 million for the same period in the
prior year.
The company’s net loss and net loss attributable to common stockholders
in the second quarter of 2017 was $4.0 million, compared to $4.6 million
in the comparable period in 2016.
For the first half of 2017, net loss attributable to common stockholders
was $8.2 million, an improvement of 16 percent over the comparable
period loss of $9.7 million in 2016. Cash on hand and liquid investments
at the end of the second quarter totaled $44.1 million.
“Our positive momentum from the first quarter continued in the second
quarter with increased revenue, decreased operating costs and a reduced
net loss,” said Raj Ketkar, president and CEO of Arcadia. “Together with
our global partners, we continue to advance the key products from our
yield trait and food ingredient platforms toward commercialization.”
Business and Technology Highlights
Arcadia made the following business and technical achievements during
the second quarter of 2017:
-
SONOVA GLA Safflower Oil Approved For Use in Dog
Food. After completing its review of Arcadia’s food additive
petition, the FDA concluded that the data supports the safety and
functionality of GLA safflower oil as a source of omega-6 fatty acids
in dry food for adult dogs. The petition will be approved when the
final rule is published in the Federal Register. This approval opens
up an expanded opportunity for use of SONOVA GLA safflower oil in pet
nutrition and demonstrates Arcadia’s strong regulatory capabilities
and commitment toward creating the greatest possible value for our
entire product portfolio. -
Eric J. Rey and Gregory D. Waller Join Arcadia
Biosciences Board Of Directors. Eric J. Rey and Gregory D.
Waller were elected at the company’s annual stockholders meeting to
replace directors Vic Knauf, Ph.D., and Rajiv Shah, M.D. Additionally,
the board of directors formally elected George F.J. Gosbee as its
chair. Gosbee had served as interim chair of the board since November
2016.
Since the close of the second quarter, Arcadia has also announced the
following achievements:
-
Arcadia and Dow AgroSciences (DAS) to
Collaborate on Improved Wheat Quality Trait. Arcadia and DAS
will jointly develop and commercialize a breakthrough improved wheat
quality trait in North America. The collaboration leverages Arcadia’s
leading non-GM TILLING trait development platform with DAS’ enabling
technology platforms, high-quality elite germplasm and global
commercial channels. -
HB4 Stress-Tolerant Soybeans Complete U.S. FDA
Safety Review. Through Verdeca, a joint venture with Bioceres,
Arcadia completed the FDA safety review for HB4 stress-tolerant
soybeans. This allows products derived from the trait to be used
commercially in human food and animal feed. This is a major milestone
in the development of this trait, which aims to create significant
value for soybean growers by bringing yield stability to areas that
experience chronic water stress problems. -
Arcadia’s Water Use Efficiency Trait Completes
US Food and Drug Administration Early Food Safety Evaluation (EFSE).
The FDA’s EFSE concluded that the functional protein for the WUE
trait, isopentenyl transferase (IPT), is safe for humans and animals
and would not raise food safety concerns if present in the food
supply. This approval is an assurance of safety for WUE crops
currently under development and being tested in the field and will
expedite the regulatory approvals for this trait. Greenhouse and field
trials of the WUE trait have been completed in agronomic crops such as
rice, wheat, cotton, peanuts and alfalfa, and Arcadia is currently
working with collaborators in rice, potato, sugarcane, cotton and
multiple tree species. -
Amy Yoder Joins Arcadia Biosciences Board of
Directors. Yoder is president and CEO of Anuvia Plant Nutrients
and the former president and CEO of Arysta LifeScience. She received a
bachelor’s degree in agricultural technology and systems management
from Michigan State University, with an emphasis in crop and soil
science.
| Arcadia Biosciences, Inc. | ||||||||||||||||||
| Financial Snapshot | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
|
($ in thousands) |
||||||||||||||||||
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||
| Favorable/ | Favorable/ | |||||||||||||||||
| 2017 | 2016 | (Unfavorable) | 2017 | 2016 | (Unfavorable) | |||||||||||||
| $ | % | $ | % | |||||||||||||||
| Total Revenues | 991 | 721 | 270 | 37% | 2,009 | 1,573 | 436 | 28% | ||||||||||
| Total Operating Expenses | 4,728 | 5,010 | 282 | 6% | 9,709 | 10,795 | 1,086 | 10% | ||||||||||
| Loss From Operations | (3,737) | (4,289) | 552 | 13% | (7,700) | (9,222) | 1,522 | 17% | ||||||||||
| Net Loss and Net Loss Attributable to Common Stockholders | (4,006) | (4,551) | 545 | 12% | (8,222) | (9,741) | 1,519 | 16% | ||||||||||
Revenues
In the second quarter of 2017, revenues were $991,000 compared to
revenues of $721,000 in the second quarter of 2016, a 37 percent
improvement. The quarter-over-quarter increase was driven by increased
product sales and additional revenue from a new contract research
agreement in 2017. In the first half of 2017, overall revenues increased
to $2.0 million from $1.6 million primarily as a result of the new
contract research agreement.
Operating Expenses
In the second quarter of 2017, operating expenses totaled $4.7 million,
down from $5.0 million in the first quarter of 2016, a decrease of
$282,000 or 6 percent. For the first half of 2017, operating expenses
were $9.7 million, compared with $10.8 million during the same period in
2016. Cost of product revenues increased by $40,000 as a result of
higher sales when comparing the respective six-month periods. Research
and development (R&D) spending decreased by $926,000 and general and
administrative (SG&A) expenses decreased by $200,000. Both expense
categories had decreases driven primarily by lower salaries and
benefits, mainly the result of workforce reductions made during 2016.
Net Loss and Net Loss Attributable to Common Stockholders
Net loss and net loss attributable to common stockholders for the second
quarter of 2017 was $4.0 million, or a loss of $0.09 per share, a 12
percent improvement from the $4.6 million loss in the second quarter of
2016. Net loss and net loss attributable to common stockholders for the
first half of 2017 was $8.2 million, compared to $9.7 million for the
first half of 2016.
Liquidity
Following the close of the second quarter, in July 2017, the Company
repaid its outstanding term loan with Silicon Valley Bank, including the
principal balance of $25.0 million, interest of $148,000, an early
prepayment fee of $500,000 and an end-of-term payment fee of $625,000.
Due to the early termination of the facility, management estimates the
company will save a total of $2.0 million in cash interest payments over
the remaining term of the original facility.
Conference Call and Webcast
The company has scheduled a conference call for 4:30 p.m. Eastern (1:30
p.m. Pacific) today, August 10, to discuss second-quarter financial
results and key strategic achievements.
Interested participants can join the conference call using the following
numbers:
| U.S. Toll-Free Dial-In: | +1-844-243-4690 | ||||
| International Dial-In: | +1-225-283-0138 | ||||
| Passcode: | 58692729 | ||||
A live webcast of the conference call will be available on the
“Investors” section of the Arcadia website at www.arcadiabio.com.
Following completion of the call, a recorded replay will be available on
the company’s investor website.
Safe Harbor Statement
“Safe Harbor” statement under the Private Securities Litigation Reform
Act of 1995: This press release and the accompanying conference call
contain forward-looking statements about the company and its products,
including statements relating to components of the company’s long-term
financial success; the company’s traits, commercial products, and
collaborations; and the company’s ability to manage the regulatory
processes for its traits and commercial products. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: the company’s and its
partners’ ability to develop commercial products incorporating its
traits and to complete the regulatory review process for such products;
the company’s compliance with laws and regulations that impact the
company’s business, and changes to such laws and regulations; and the
company’s future capital requirements and ability to satisfy its capital
needs. Further information regarding these and other factors that could
affect the company’s financial results is included in filings the
company makes with the Securities and Exchange Commission from time to
time, including the section entitled “Risk Factors” in the company’s
Annual Report on Form 10-K for the year ended December 31, 2016. These
documents are on the SEC Filings section of the “Investors” section of
the company’s website at www.arcadiabio.com.
All information provided in this release and in the attachments is as of
the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to
update this information.
About Arcadia Biosciences, Inc.
Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops
agricultural products that create added value for farmers while
benefitting the environment and enhancing human health. Arcadia’s
agronomic performance traits, including Nitrogen Use Efficiency, Water
Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide
Tolerance, are all aimed at making agricultural production more
economically efficient and environmentally sound. Arcadia’s nutrition
traits and products are aimed at creating healthier ingredients and
whole foods with lower production costs. For more information, visit www.arcadiabio.com.
| Arcadia Biosciences, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (Unaudited) | |||||||
|
(In thousands, except share data) |
|||||||
| June 30, | December 31, | ||||||
| 2017 | 2016 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 13,438 | $ | 2,013 | |||
| Short-term investments | 30,740 | 48,547 | |||||
| Accounts receivable | 432 | 349 | |||||
| Unbilled revenue | 141 | 184 | |||||
| Inventories — current | 286 | 252 | |||||
| Prepaid expenses and other current assets | 1,480 | 877 | |||||
| Total current assets | 46,517 | 52,222 | |||||
| Property and equipment, net | 417 | 508 | |||||
| Inventories — noncurrent | 1,153 | 1,327 | |||||
| Long-term investments | — | 2,498 | |||||
| Other noncurrent assets | 346 | 19 | |||||
| Total assets | $ | 48,433 | $ | 56,574 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable and accrued expenses | $ | 1,834 | $ | 2,359 | |||
| Amounts due to related parties | 27 | 30 | |||||
| Notes payable — current | 4,167 | — | |||||
| Unearned revenue — current | 666 | 740 | |||||
| Total current liabilities | 6,694 | 3,129 | |||||
| Notes payable — noncurrent | 21,058 | 25,127 | |||||
| Unearned revenue — noncurrent | 2,920 | 3,120 | |||||
| Other noncurrent liabilities | 3,000 | 3,000 | |||||
| Total liabilities | 33,672 | 34,376 | |||||
| Stockholders’ equity: | |||||||
|
Common stock, $0.001 par value—150,000,000 and 400,000,000 shares authorized as of June 30, 2017 and December 31, 2016; 42,664,821 and 44,487,678 shares issued and outstanding as of June 30, 2017 and December 31, 2016 |
43 | 44 | |||||
| Additional paid-in capital | 174,503 | 173,723 | |||||
| Accumulated deficit | (159,772 | ) | (151,550 | ) | |||
| Accumulated other comprehensive loss | (13 | ) | (19 | ) | |||
| Total stockholders’ equity | 14,761 | 22,198 | |||||
| Total liabilities and stockholders’ equity | $ | 48,433 | $ | 56,574 | |||
| Arcadia Biosciences, Inc. | ||||||||||||||||
|
Condensed Consolidated Statements of Operations and Comprehensive Loss |
||||||||||||||||
| (Unaudited) | ||||||||||||||||
|
(In thousands, except share and per share data) |
||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product | $ | 195 | $ | 65 | $ | 400 | $ | 320 | ||||||||
| License | 103 | 140 | 209 | 292 | ||||||||||||
| Contract research and government grants | 693 | 516 | 1,400 | 961 | ||||||||||||
| Total revenues | 991 | 721 | 2,009 | 1,573 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of product revenues | 116 | 35 | 222 | 182 | ||||||||||||
| Research and development | 1,669 | 2,216 | 3,492 | 4,418 | ||||||||||||
| Selling, general and administrative | 2,943 | 2,759 | 5,995 | 6,195 | ||||||||||||
| Total operating expenses | 4,728 | 5,010 | 9,709 | 10,795 | ||||||||||||
| Loss from operations | (3,737 | ) | (4,289 | ) | (7,700 | ) | (9,222 | ) | ||||||||
| Interest expense | (365 | ) | (327 | ) | (704 | ) | (654 | ) | ||||||||
| Other income, net | 104 | 76 | 200 | 152 | ||||||||||||
| Net loss before income taxes | (3,998 | ) | (4,540 | ) | (8,204 | ) | (9,724 | ) | ||||||||
| Income tax provision | (8 | ) | (11 | ) | (18 | ) | (17 | ) | ||||||||
|
Net loss and net loss attributable to common stockholders |
$ | (4,006 | ) | $ | (4,551 | ) | $ | (8,222 | ) | $ | (9,741 | ) | ||||
| Net loss per share attributable to common stockholders: | ||||||||||||||||
| Basic and diluted | $ | (0.09 | ) | $ | (0.10 | ) | $ | (0.19 | ) | $ | (0.22 | ) | ||||
|
Weighted-average number of shares used in per share calculations: |
||||||||||||||||
| Basic and diluted | 42,664,821 | 44,308,245 | 43,572,936 | 44,274,508 | ||||||||||||
| Other comprehensive income, net of tax | ||||||||||||||||
|
Unrealized gains on available-for-sale securities
|
7 | 25 | 6 | 109 | ||||||||||||
| Other comprehensive income | 7 | 25 | 6 | 109 | ||||||||||||
|
Comprehensive loss attributable to common stockholders |
$ | (3,999 | ) | $ | (4,526 | ) | $ | (8,216 | ) | $ | (9,632 | ) | ||||
| Arcadia Biosciences, Inc. | ||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (Unaudited) | ||||||||
|
(In thousands) |
||||||||
| Six Months Ended June 30, | ||||||||
| 2017 | 2016 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (8,222 | ) | $ | (9,741 | ) | ||
|
Adjustments to reconcile net loss to cash used in operating activities: |
||||||||
| Depreciation and amortization | 146 | 147 | ||||||
| Gain on disposal of equipment | (3 | ) | — | |||||
| Net amortization of investment premium and discount | (65 | ) | 139 | |||||
| Stock-based compensation | 760 | 393 | ||||||
| Accretion of debt discount | 99 | 98 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (83 | ) | 529 | |||||
| Unbilled revenue | 43 | (10 | ) | |||||
| Inventories | 140 | (19 | ) | |||||
| Prepaid expenses and other current assets | (603 | ) | (670 | ) | ||||
| Other noncurrent assets | (327 | ) | (67 | ) | ||||
| Accounts payable and accrued expenses | (525 | ) | 195 | |||||
| Amounts due to related parties | (3 | ) | (4 | ) | ||||
| Unearned revenue | (274 | ) | 163 | |||||
| Net cash used in operating activities | (8,917 | ) | (8,847 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Proceeds from sale of property and equipment | 4 | — | ||||||
| Purchases of property and equipment | (58 | ) | (198 | ) | ||||
| Purchases of investments | (19,405 | ) | — | |||||
| Proceeds from sales and maturities of investments | 39,785 | 12,205 | ||||||
| Net cash provided by investing activities | 20,326 | 12,007 | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Payments of debt issuance costs | — | (46 | ) | |||||
| Proceeds from exercise of stock options and ESPP purchases | 16 | 273 | ||||||
| Net cash provided by financing activities | 16 | 227 | ||||||
| Net increase in cash and cash equivalents | 11,425 | 3,387 | ||||||
| Cash and cash equivalents — beginning of period | 2,013 | 23,973 | ||||||
| Cash and cash equivalents — end of period |
$ |
13,438 |
$ | 27,360 | ||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for interest | $ | 599 | $ | 474 | ||||
| Cash paid for income taxes | $ | 1 | $ | 2 | ||||
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
|
Exchange of membership interest in unconsolidated entity for common stock |
$ | 2 | $ | — | ||||
| Stock option exercise cost included in accounts receivable | $ | — | $ | 30 | ||||
Contacts
Arcadia Biosciences, Inc.
Jeff Bergau
[email protected]
+1-312-217-0419
.png)
